PhageLab
Year2024
RoundSeries A
Amount$11M
Overall
Summary
26 slides
26 slides
1 slide
PhageLab® is an AI-powered biotech platform focused on combating the global bacterial threat.
1 slide
Our solution, highlighted in a reputable scientific journal, shows high efficacy in targeting Salmonella.
7 slides
Antibiotics are becoming ineffective, leading to an imminent global health catastrophe. Meat consumption continues to grow, reliant heavily on antibiotics, while Big Pharma is backing away from new antibiotic development.
1 slide
The antibacterial resistance issue creates a significant, growing market ready for disruption, valued at $104 billion.
4 slides
PhageLab offers a fast, safe, and effective solution using bacteriophages, nature's way of fighting bacteria. Our platform customizes solutions within 45 days.
1 slide
Our patented epidemiological analysis algorithm and extensive repositories offer unmatched data and capabilities.
2 slides
PhageLab has showcased efficacy in field trials, eliminating up to 100% of Salmonella presence.
4 slides
Our diverse team of nearly 100 people operates out of LATAM and the EU, led by experienced founders and executives with extensive industry experience.
1 slide
With ineffective antibiotics, the world faces a dire MDR threat. PhageLab provides a scalable, effective solution to disrupt a $104B market using phages and advanced AI.
1 slide
Science works and we can prove it.
1 slide
2 slides
Learn more about our process, lab, and the antibiotic crisis.
